FGFR2 AMPLIFICATION Detail (hg19) (FGFR2)

Information

Genome

Assembly Position
hg19 chr10:123,239,371-123,357,917
hg38 chr10:121,479,857-121,598,403 View the variant detail on this assembly version.
Summary

MGeND

Clinical significance
Variant entry
GWAS entry
Disease area statistics Show details

ClinVar

Clinical Significance
Review star [No Data.]
Show details
Links
Type Database ID Link
Gene MIM 176943 OMIM
HGNC 3689 HGNC
Ensembl ENSG00000066468 Ensembl
NCBI NCBI
Gene Cards Gene Cards
OncoKB OncoKB
Type Database ID Link
Variant TogoVar
COSMIC
MONDO
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
Disease Drug EL ET ED CS VO TR Pubmed Links
breast cancer Dovitinib B Predictive Supports Sensitivity/Response N/A 2 23658459 Detail
stomach carcinoma FGFR Inhibitor AZD4547 B Predictive Supports Sensitivity/Response N/A 3 27179038 Detail
DisGeNET
[No Data.]
Annotation

Annotations

DescrptionSourceLinks
Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited prolifera... CIViC Evidence Detail
Nine patients with FGFR2-amplified gastroesophageal cancer were treated with AZD4547. Of these 9 pa... CIViC Evidence Detail

Overlapped Transcript Coordinates

Gene Transcript ID Exon Number Chromosome Start Stop Type Amino Mutation Transcript Position Links

Overlapped Transcript

Gene Transcript ID Chromosome Start Stop Links
Gene
FGFR2
Genome
hg19
Position
chr10:123,239,371-123,357,917
Variant Type
cnv
Variant (CIViC) (CIViC Variant)
AMPLIFICATION
Transcript 1 (CIViC Variant)
ENST00000457416.2
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/629
Genome browser